Updated Aug 22, 2018

Default inno

Development, Laboratory Testing and Field Validation of a Rapid Diagnostic Test for Ebola Virus Disease

Part of Makerere University

Imagine a cheap, easy to use, rapid diagnostic test (RDT) for detecting two genera of viruses that cause the world's most dreaded and fatal hemorrhagic fevers ( Ebolavirus and Marburgvirus) at the point-of-care in equatorial African villages

https://www.scidev.net/sub-saharan-africa/health/news/scientists-developing-rapid-test-kit-for-ebola-virus.html
Default avatar

Misaki Wayengera

Send Message

Stage 4: Transition to Scale

Focus Areas:

Infectious & Vector Diseases, Medical Devices and Social Development

Infectious & Vector Diseases, Medical Devices and Social DevelopmentSEE LESS

Implemented In:

Uganda

UgandaSEE LESS

1
Key Partner
1
Country Implemented In
995,694,907
Customers
5
Employee
$689,250
Funds Raised to Date
Verified Funding
?

Problem

Two generic members of the Filoviridae family of RNA viruses-Ebolavirus and Marburgvirus (EBOV & MARV) cause rare but highly fatal viral hemorrhagic fevers (VHFs) in remote villages of equatorial Africa. There is a critical need for cheap, easy to use rapid diagnostic tests (RDTs) for early detection of VHFs at the point-of- care (POC). Whereas two RDTs for EBOV have emerged, duo-purpose RDTs for both EBOV and MARV are absent.

}

Solution

We aimed to synthesis, test and profile an inventory of monoclonal antibodies (mAbs) for the research and development (R & D) of a dual purpose rapid diagnostic test (RDT) for filovirus associated VHFs. Prototypres of RDTs have been developed. We are currently validating reagents with vero-expressed Sudan Ebolavirus virions in the P4 at the Center for Emerging Zoonotic Diseases, National Institute for Communicable Diseases (NICD), Johanesburg, South Africa

Target Beneficiaries

Following the West African Ebola Virus Disease (EVD) pandemic that threatened to spread globally, EBOV and its sister genera MARV are pathogens of public health concern internationally. Thus, while the immediate primary beneficiaries are populations of equatorial African villages and their government ministries of health, populations and governments elsewhere are potential secondary users. At the tertiary level are global health promotion bodies such as the WHO and CDC

Mission and Vision

To produce a cheap, easy to use, rapid diagnostic test (RDT) for duo-detectiion of the two genera of viruses that cause the world's most dreaded and fatal hemorrhagic fevers ( Ebolavirus and Marburgvirus) at the point-of-care in equatorial African villages

Innovation Description

This is a paper strip test that gives results in 2-5 minutes. Several prototypes are being fronted including the Antigen kit, and Antibody (IgM) kit. An IgG kit for epidemiological studies is considered

Competitive Advantage

This is the first duo-purpose RDT, targeting both EBOV and MARV, and detecting a portion of the filovirus glycoprotein that is also used in vaccination. Therefore, this assay can be used to detected responses to EBOV vaccines.

Planned Goals and Milestones

Receiver operator characterizationof novel EBOV/MARV-GP epitopes using 2014-2015 Sierra Leonian Ebola patient samples at the NICD BSL-IV
Funding Goal5,000,000
New Implemented CountriesCongo, Democratic Republic of the
Recruit3 Senior Scientists, Executive, Sales Personnel, Board of Directors, 5 junior scientists (assistants)
New FeatureMultiplexing with existing RDTs that detect other causes of hemorrhagic fevers

Milestones

Jul 2018
Key Partnership
as part of
Career Development Grant
Mar 2014
Date Unknown
New Country Implemented In
Uganda

Supporting Materials

WO2016079572A1-Conserved-b-cell-epitopes-of-filovirus-glycoprotein-and-their-use-as-either-biomarkers-or-therapeutics-and-sub-unit-vaccines-for-ebola-virus-and-marburg-virus-Google-Patents.pdf